Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior ...

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...